Тяжелое поражение подоцитов, выявленное при электронной микроскопии почечного биоптата, у пациента с болезнью Фабри без выраженных изменений мочи и почечной недостаточности
- Авторы: Фомин ВВ1, Пулин АА1, Аксенова ОА1, Кустова ТЮ1, Гирина СС1, Рощупкина СВ1, Кудрявцев ВА1, Варшавский ВА1, Голицына ЕП1, Дамулин ИВ1, Панасюк ВВ1, Мухин НА1, Fomin VV1, Pulin AA1, Aksenova OA1, Kustova TY.1, Girina SS1, Roschupkina SV1, Kudravtsev VA1, Varshavskii VA1, Golitsina EP1, Damulin IV1, Panasiuk VV1, Mukhin NA1
-
Учреждения:
- Выпуск: № 1 (2012)
- Страницы: 55-58
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2075-3594/article/view/261713
- ID: 261713
Цитировать
Полный текст
Аннотация
Ключевые слова
Об авторах
В В Фомин
А А Пулин
О А Аксенова
Т Ю Кустова
С С Гирина
С В Рощупкина
В А Кудрявцев
В А Варшавский
Е П Голицына
И В Дамулин
В В Панасюк
Н А Мухин
V V Fomin
A A Pulin
O A Aksenova
T Yu Kustova
S S Girina
S V Roschupkina
V A Kudravtsev
V A Varshavskii
E P Golitsina
I V Damulin
V V Panasiuk
N A Mukhin
Список литературы
- Jefferson J.A., Nelson P.J., Najafian B. et al. Podocyte disorders: Core Curriculum 2011. Am. J. Kidney Dis. 2011; 58(4): 666-677.
- Fogo A.B., Bostad L., Svarstad E. et al.; all members of the International Study Group of Fabry Nephropathy (ISGFN). Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol. Dial. Transplant. 2010; 25(7): 2168-2177.
- Sessa A., Meroni M., Battini G. et al.; Studio Multicentrico Italiano sulla Malattia di Anderson-Fabry. Evolution of renal pathology in Fabry disease. Acta. Paediatr. Suppl. 2003; 92(443):6-8.
- Fischer E.G., Moore M.J., Lager D.J. Fabry disease: a morphologic study of 11 cases. Mod. Pathol. 19(10): 1295-1301.
- Sanchez-Niño M.D., Sanz A.B., Carrasco S. et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol. Dial. Transplant. 2011; 26(6): 1797-1802.
- Valbuena C., Carvalho E., Bustorff M. et al. Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy. Virchows Arch. 2008; 453(4):329-338.
- Valbuena C., Oliveira J.P., Carneiro F. et al. Kidney histologic alterations in α-Galactosidase-deficient mice. Virchows Arch. 2011; 458(4): 477-486.
- Sessa A., Meroni M., Battini G. et al. Renal pathological changes in Fabry disease. J. Inherit. Metab. Dis. 2001;24(Suppl. 2): 66-70.
- Najafian B., Svarstad E., Bostad L. et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney Int. 2011; 79(6): 663-670.
- Asahi K., Katoh T., Watanabe K. et al. Fabry disease with few clinical signs and symptoms. Intern. Med. 2002; 41(11): 983-985.
- Meehan S.M., Junsanto T., Rydel J.J. et al. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications. Am. J. Kidney Dis. 2004; 43(1): 164-171.
- Christensen E.I., Zhou Q., Sørensen S.S. et al. Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice. J. Am. Soc. Nephrol. 2007; 18(3): 698-706.
- Thurberg B.L., Rennke H., Colvin R.B. et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002; 62(6): 1933-1946.
- Prabakaran T., Nielsen R., Larsen J.V. et al. Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease. PLoS One. 2011;6(9):e25065.
- Choi J.O., Lee M.H., Park H.Y. et al. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer. J. Biomed. Sci. 2010; 17: 26.
- Germain D.P., Waldek S., Banikazemi M. et al. Sustained, long-term renal stabilization after 54 moths of agalsidase b therapy in patients with Fabry disease. J. Am. Soc. Nephrol. 2007; 18: 1547-1557.
- Wanner C., Oliveira J.P., Ortiz A. et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin. J. Am. Soc. Nephrol. 2010; 5(12): 2220-2228.
- Warnock D.G., Ortiz A., Mauer M. et al.; on behalf of the Fabry Registry. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant. 2011 Jul 29. [Epub ahead of print].
Дополнительные файлы
